Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 4/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.32 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25031556 | 1.00 | HDAC1 (0.32) | HDAC1HDAC2HDAC6KDM5APHF8 | |
| SCHEMBL25755991 | 1.00 | HDAC1 (0.32) | HDAC1HDAC2HDAC6KDM5APHF8 | |
| SCHEMBL25031758 | 0.91 | HDAC1 (0.32) | HDAC1HDAC2HDAC6 | |
| SCHEMBL25756043 | 0.89 | HDAC1 (0.31) | HDAC1HDAC2HDAC6KDM5A | |
| SCHEMBL25773087 | 0.89 | — | — | |
| SCHEMBL25756091 | 0.89 | — | — | |
| SCHEMBL25031557 | 0.87 | USP2 (0.34) | HDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL25755995 | 0.87 | USP2 (0.34) | HDAC1HDAC2HDAC6ALDH1A1 | |
| SCHEMBL25771561 | 0.87 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL25755938 | 0.87 | L3MBTL1 (0.33) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | HDAC1 596/4885HDAC2 1263/4885HDAC6 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.